BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37800378)

  • 21. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
    Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
    Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor Location in the Pancreatic Tail Is Associated with Decreased Likelihood of Receiving Chemotherapy for Pancreatic Adenocarcinoma.
    Drake JA; Fleming AM; Behrman SW; Glazer ES; Deneve JL; Yakoub D; Tsao MW; Dickson PV
    J Gastrointest Surg; 2022 Oct; 26(10):2136-2147. PubMed ID: 35768717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
    Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
    Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases.
    Altman AM; White MJ; Marmor S; Shukla D; Chang K; Lou E; LaRocca CJ; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
    Cancer Control; 2022; 29():10732748221109991. PubMed ID: 35839251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Why the Treatment Sequence Matters: Interplay Between Chemotherapy Cycles Received, Cumulative Dose Intensity, and Survival in Resected Early-stage Pancreas Cancer.
    Wu VS; Elshami M; Stitzel HJ; Lee JJ; Hue JJ; Kyasaram RK; Hardacre JM; Ammori JB; Winter JM; Selfridge JE; Mohamed A; Chakrabarti S; Bajor D; Mahipal A; Ocuin LM
    Ann Surg; 2023 Oct; 278(4):e677-e684. PubMed ID: 37071769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base.
    Cassidy RJ; Liu Y; Patel K; Zhong J; Steuer CE; Kooby DA; Russell MC; Gillespie TW; Landry JC
    Cancer; 2017 Mar; 123(5):783-793. PubMed ID: 27780316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database.
    Hamad A; Underhill J; Ansari A; Thayaparan V; Cloyd JM; Li Y; Pawlik TM; Tsung A; Abushahin L; Ejaz A
    Surgery; 2022 Jun; 171(6):1464-1470. PubMed ID: 35115154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
    Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN
    HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.
    Jiang W; Haque W; Verma V; Butler EB; Teh BS
    Acta Oncol; 2019 Sep; 58(9):1259-1266. PubMed ID: 31237185
    [No Abstract]   [Full Text] [Related]  

  • 30. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.
    Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
    Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer.
    Benjamin AJ; Buschmann MM; Zhang SQ; Wroblewski K; Kindler HL; Roggin KK; Dale W
    J Geriatr Oncol; 2018 Jul; 9(4):367-372. PubMed ID: 29534880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer.
    Leonhardt CS; Pils D; Qadan M; Gustorff C; Sahora K; Klaiber U; Warshaw AL; Prager G; Ferrone CR; Lillemoe KD; Schindl M; Strobel O; Castillo CF; Hank T
    Eur J Cancer; 2023 Nov; 193():113293. PubMed ID: 37713740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
    Janssen QP; van Dam JL; Doppenberg D; Prakash LR; van Eijck CHJ; Jarnagin WR; O' Reilly EM; Paniccia A; Besselink MG; Katz MHG; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B;
    J Natl Cancer Inst; 2022 May; 114(5):695-703. PubMed ID: 35157075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In search of lost time: Delays in adjuvant therapy for pancreatic adenocarcinoma among under-resourced patient populations.
    Hamad A; Eskander MF; Shen C; Bhattacharyya O; Fisher JL; Oppong BA; Obeng-Gyasi S; Tsung A
    Surgery; 2022 Sep; 172(3):982-988. PubMed ID: 35595567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disparities in Receipt of Adjuvant Therapy After Upfront Surgical Resection for Pancreatic Ductal Adenocarcinoma.
    Anteby R; Blaszkowsky LS; Hong TS; Qadan M
    Ann Surg Oncol; 2023 Apr; 30(4):2473-2481. PubMed ID: 36585536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.
    Hue JJ; Sugumar K; Markt SC; Hardacre JM; Ammori JB; Rothermel LD; Winter JM; Ocuin LM
    Surgery; 2021 Jul; 170(1):207-214. PubMed ID: 33454134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based on Pathologic Features.
    Moaven O; Clark CJ; Russell GB; Votanopoulos KI; Howerton R; Levine EA; Shen P
    Ann Surg; 2021 Dec; 274(6):1058-1066. PubMed ID: 31913868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant Chemotherapy After Neoadjuvant Chemotherapy for Pancreatic Cancer is Associated with Improved Survival for Patients with Low-Risk Pathology.
    Olecki EJ; Stahl KA; Torres MB; Peng JS; Dixon M; Shen C; Gusani NJ
    Ann Surg Oncol; 2021 Jun; 28(6):3111-3122. PubMed ID: 33521899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
    Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A
    JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.